Economic aspects of antimicrobial therapy of acute exacerbations of COPD.

[1]  M. Miravitlles,et al.  Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. , 2005, Respiratory medicine.

[2]  C. Lucioni,et al.  I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD) , 2005 .

[3]  F. Martinez,et al.  Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. , 2005, The American journal of medicine.

[4]  A. Ferrara.  New Fluoroquinolones in Lower Respiratory Tract Infections and Emerging Patterns of Pneumococcal Resistance , 2005, Infection.

[5]  M. Miravitlles,et al.  Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care , 2004, International journal of clinical practice.

[6]  M. R. Rutten-van Mölken,et al.  Resource use and risk factors in high-cost exacerbations of COPD. , 2004, Respiratory medicine.

[7]  D. Felmingham.  Comparative Antimicrobial Susceptibility of Respiratory Tract Pathogens , 2004, Chemotherapy.

[8]  M. Miravitlles,et al.  Estudio farmacoeconómico del tratamiento antibiótico de las agudizaciones de la bronquitis crónica y la EPOC en Latinoamérica , 2003 .

[9]  C. Chang,et al.  Equal Effectiveness of Older Traditional Antibiotics and Newer Broad-Spectrum Antibiotics in Treating Patients with Acute Exacerbations of Chronic Bronchitis , 2003, Southern medical journal.

[10]  B. Varkey,et al.  Evidence-based approach to acute exacerbations of COPD. , 2003, Current opinion in pulmonary medicine.

[11]  M. Decramer,et al.  Management of COPD according to guidelines. A national survey among Belgian physicians. , 2003, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[12]  L. Mandell,et al.  Canadian guidelines for the management of acute exacerbations of chronic bronchitis. , 2003, Canadian respiratory journal.

[13]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[14]  M. Zodet,et al.  Cost-effectiveness of gemifloxacin: results from the GLOBE study. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  P. Kardas.  Patient compliance with antibiotic treatment for respiratory tract infections. , 2002, The Journal of antimicrobial chemotherapy.

[16]  Ramon Gisbert,et al.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.

[17]  J. Gaillat.  Quels objectifs pour l'antibiothérapie dans les exacerbations aiguës de la bronchite chronique? , 2001 .

[18]  M. Habib.  Management of Clinical Failures in Non-ICU Patients with Chronic Obstructive Pulmonary Disease Exacerbations , 2001, Chemotherapy.

[19]  A. Gray,et al.  The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  M. Miravitlles,et al.  Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. , 2001, The European respiratory journal.

[21]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[22]  D. Mccrory,et al.  Management of acute exacerbations of COPD: a summary and appraisal of published evidence. , 2001, Chest.

[23]  J. Lorenz,et al.  [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study]. , 2001, Deutsche medizinische Wochenschrift.

[24]  F. Martinez,et al.  Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy , 2001, Clinical Therapeutics.

[25]  E. Spiritus.  Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure. , 2000, The American journal of managed care.

[26]  S. Sethi.  Infectious etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.

[27]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[28]  C. Bennett,et al.  Nosocomial tuberculosis prevention measures among two groups of US hospitals, 1992 to 1996. , 2000, Chest.

[29]  C. Lavie,et al.  Benefits of cardiac rehabilitation and exercise training. , 2000, Chest.

[30]  J. C. Campbell,et al.  Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. , 1999, The Journal of antimicrobial chemotherapy.

[31]  M. Niederman,et al.  Treatment cost of acute exacerbations of chronic bronchitis. , 1999, Clinical therapeutics.

[32]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[33]  L. Lacey,et al.  Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany , 1998 .

[34]  R. Cook,et al.  A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. , 1998, Chest.

[35]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[36]  M. Goldacre,et al.  In-patient workload in medical specialties: 2. Profiles of individual diagnoses from linked statistics. , 1995, QJM : monthly journal of the Association of Physicians.

[37]  E. Vittinghoff,et al.  Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. , 1995, JAMA.

[38]  R. Wilson,et al.  Chemotherapy for chronic bronchitis. Controversies. , 1995, Presse medicale.

[39]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[40]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.